

Analytical Method Validation in Pharmaceutical Quality Control: Current Guidelines and Challenges

Perli Kranti Kumar^{1*}, Prashik B Dudhe¹, Shrikant S Nilewar¹

¹School of Pharmaceutical Sciences, Sandip University, Nashik, Maharashtra, 422213

*Corresponding Email: drpkk1987@gmail.com

Abstract

Analytical method validation (AMV) in the veterinary field forms an important aspect of quality control in pharmaceutical companies in which drugs are used to treat various species of animals to guarantee safety, efficacy and regulatory actions are adhered to. This review points to the significance of the species-based approaches in pharmacokinetics of drug absorption, distribution, metabolism, and residue detection with a focus on the issues of physiological diversity, complex biological samples and ethical requirement. Modern methods such as HPLC, UPLC, GC, LC-MS/MS, UV-Vis, and FTIR are characterized by sensitivity, specificity, and reproducibility and newer techniques such as capillary electrophoresis and microfluidic-based technology, high-resolution mass spectrometry and bioinformatics-directed validation incorporates enhanced sensitivity, specificity, reproducibility, reduced sample volumes, and increased throughput. Future methodological advances in multi-dimensional platforms, green analytical chemistry, chemometrics, and machine learning offer new ways of addressing matrix effects and resource limitations and regulatory limitations. Taken together, these strategies can contribute to effective veterinary drug monitoring, food safety, and sustainable and species-specific AMV practices and direct future research at achieving harmonized and technologically more advanced validation processes.

Key Words:

Veterinary Pharmaceuticals, Analytical Method Validation, Species-Specific Validation, LC-MS/MS, Microfluidics, Chemometrics, Residue Monitoring, Green Analytical Chemistry

History:

Received: April, 23, 2025

Revised: June, 18, 2025

Accepted: July, 11, 2025

Published: Aug 25, 2025

DOI: <https://doi.org/10.64063/3049-1681.vol.2.issue8.3>

1. INTRODUCTION

Veterinary pharmaceuticals have expanded at a very fast rate to accommodate the health and productivity of various animal life, which range between livestock, companion animals and sea life. Unlike human drugs and medicines, novel veterinary pharmacopoeia has to take into consideration species physiological differences, metabolic rates and tissue balances all of which affect drug absorption, distribution, metabolism and excretion parameters¹. Such differences increase the work and complicate the development and validation of analytical methods that have to be carefully adjusted to the animal species and the type of sample. Observations in drug quality,

Journal of Pharmaceutical Research and Integrated Medical Sciences (JPRIMS)

ISSN: 3049-1681 | Vol. 02 Issue 08, Aug-2025 | pp. -26-39

efficacy and safety in animals are important to not only ensure health of the animals but also that confronted residue does not leak into the human food chain.



Figure 1: Veterinary Pharmaceuticals²

Reviewing research that uses animals as the subjects of study, it is also paramount to the firm development of pharmacokinetics, residue tracking and optimization of therapies. The use of validated methods of analysis means that low and high doses of drugs can be precisely measured in blood, organs, milk, etc. and validated responses guarantee compliance with regulation, as well as scientific knowledge. Advances in veterinary pharmaceutical quality control make species-specific method validation a vital component of veterinary pharmaceutical quality control and the growing complexity of veterinary matrices and the growing precision required in residue detection are directing advances in analytical technologies³.

1.1 Background Information and Context

Quality control in pharmaceuticals: Pharmaceutical quality control is important to make sure that the product is safe, effective, and consistent. Within the veterinary medical field, it is especially important because of the multiplicity of species being treated with each species having unique metabolic and physiological attributes⁴. The basis of veterinary pharmaceutical quality control is analytical method validation (AMV) and its standard methods of quantifying drugs, residue monitoring, and appropriate dose across livestock, companion animals, and aquaculture. In contrast to human-based pharmaceuticals, veterinary formulations have to take into account species-specific metabolism, tissue matrices that are diverse, and different routes of drug delivery creating a complex scenario in terms of method development and validation requirements⁵.

1.2 Objectives of the Review

The main objectives of this review are:

- To evaluate species-specific considerations in veterinary analytical method validation (AMV) and their impact on drug absorption, distribution, metabolism, and residue detection.

- To summarize current regulatory guidelines and international frameworks (VICH, FDA, EMA, ICH) applicable to veterinary AMV.
- To review and analyze advanced analytical techniques, including HPLC, UPLC, LC-MS/MS, capillary electrophoresis, microfluidics, and high-resolution mass spectrometry, for veterinary drug and residue monitoring.
- To identify challenges and gaps in veterinary AMV, including matrix variability, ethical constraints, lack of species-specific guidelines, and resource-intensive method development.
- To explore emerging trends and innovations such as bioinformatics, chemometrics, green analytical chemistry, and high-throughput approaches for improving precision, efficiency, and sustainability in veterinary AMV.

1.3 Importance of the Topic

This review is significant because it considers quality assurance of veterinary drugs which guarantees animal health and welfare as well as public health in that it prevents drug remnants in meat and milk products of animal source. This review serves as a guideline to researchers, regulatory bodies, and practitioners on how to improve more resilient, species-specific analytical validation practices by unifying the existing knowledge and underscoring new trends⁶.

2. VETERINARY ANALYTICAL METHOD VALIDATION: GUIDELINES, METHODOLOGIES, AND CURRENT RESEARCH INSIGHTS

The number of international and regional frameworks, such as VICH, FDA or EMA, leads to the accuracy, precision and specificity of the various validated analyses and, consequently, to the compliance with the regulatory requirements observed across animal matrices. The HPLC, UPLC, GC, UV-Vis, FTIR, and LC-MS/MS techniques can be used to analyze drugs, residues, and herbal compounds in a sensitive, reproducible and matrix-adapted manner in poultry, as well as aquaculture⁷. There have been key studies that show that they are effective in the presence of flavonoids, detection of antibiotic residues, and antiparasitic measurement. Although these procedures are sensitive and highly versatile, they are not without challenges such as intraspecies variation, matrix effect as well as lack of comprehensive species-specific protocols and optimization and harmonization are still required.




Figure 2: Veterinary Drug Residues in Animal⁸

2.1 Regulatory Guidelines for Veterinary Analytical Methods

The veterinary analytical methods validation (AMV) is informed by a mix of the international and regional regulatory framework aimed to ensure the safety, efficacy, and quality of the veterinary medicines. VICH GL2 and GL7 are harmonized international standards, which are aimed at validation of analytical procedures and specific veterinary product stability testing⁹. Such guidelines also focus on the aspects of accuracy, precision, specificity, linearity, and robustness so that the methods can be trustworthy among different labs and could be used in regulatory submissions. FDA and EMA veterinary guidelines also emphasize performance parameters of a method, such as reproducibility, sensitivity, and selectivity and discuss the issues specific to a particular animal matrix such as blood, milk, tissues, and excreta. Despite being human centered, the principles of the ICH Q2(R2), such as suitability of the system, calibration, or validation strategies of the methods are commonly modified in the veterinary research setting, and can serve as a guide to building confidence in the outcome of the analysis. In general, these recommendations are cumulatively allowing ease in regulatory compliance, yet because of the species-specific physiological distinctiveness, attention still must be given in method development¹⁰.

2.2 Methodologies in Veterinary AMV

Various high technologies are employed in analytical techniques of veterinary pharmacology. The High-Performance Liquid Chromatography (HPLC), Ultra-Performance Liquid Chromatography (UPLC) and Gas Chromatography (GC) are being used widely as a quantitative method to determine the drugs, feed additives and residues in a complex biological matrix such as the plasma, serum and also the tissue samples¹¹. These methods are characterized by high resolution, sensitivity, good reproducibility and as such are best suited in pharmacokinetic and residue studies. Spectroscopic techniques, such as UV-Visible (UV-Vis) spectroscopy, Fourier Transform Infrared (FTIR) spectroscopy and mass spectrometry, can be utilized to provide exceptionally sensitive, fast and in many cases non-destructive determination of active compounds or metabolites. Moreover, there is a strong importance of bioanalytical validation, especially in pharmacokinetic profiling, tissue residue depletion studies, and species-specific safety concerns, and thus pay attention to the extraction efficiency and detection limits and matrix effects. When these methodologies are well validated, then they are the core of reliable veterinary drug residue analysis and monitoring¹².

2.3 Key Research Studies

Some recent studies exemplify how these methods can be used and in what context they are effective in the practice of veterinary:

- **Herbal extract in poultry containing flavonoids:** Bioactive flavonoids in poultry feed supplements were quantified by a validated HPLC assay. The studies were very adequately satisfied with respect to accuracy and repeatability in use among various species of birds showing the usefulness of chromatographic validation method with respect to phytochemical analysis¹³.

- **Veterinary antibiotics in bovine milk:** It was analyzed by LC-MS/MS using a high-specific and sensitive method that avoided matrix interferences, and allowed consistent determination of residues to ensure compliance with maximum residue limits (MRLs).
- **Antiparasitic medicines in fish farming:** The UV-Vis and HPLC validation of liver and muscle tissues have ensured linearity, robustness, and reproducibility, which demonstrates that method optimization is critical to a wide variety of aquatic samples in fish farming¹⁴.

The collective work in these studies demonstrates how modern analytical methods are flexible to a variety of veterinary species and matrices, but that methods must be rigorously validated to guarantee desirable results¹⁵.

2.4 Strengths and Weaknesses of Current Approaches

Strengths:

- Modern analytical tools have great sensitivity and specificity, so they are vital in the detection of trace-level residues in complicated matrices.
- Under ideal standardization, methods can be reproduced in other laboratories and improve assurance that the methods would be compliant with regulation.
- The techniques are largely usable in monitoring of residues in food producing animals in support of food safety and public health goals¹⁶.

Weaknesses:

- Direct transference of methods validated and developed in one species to another must be adjusted by further optimization because of inter species variation in metabolism and physiology.
- Although harmonization has been made internationally on regulatory rules, guidelines have been weak in meeting species-specific requirements leading to infrequent consistency of validation methods.
- This is because matrix effects, fine-tuning of samples, and interference due to endogenous compounds can affect accuracy and increase risk of analytical errors, particularly in highly lipid or protein-containing tissues.

Nevertheless, there is a need to continue research and harmonization to achieve the challenges that are species-specific, complexities of matrices, and novel therapeutic compounds that are present in the current analytical approaches currently available in veterinary pharmacology¹⁷.

3. SPECIES-SPECIFIC VALIDATION, ADVANCED TECHNIQUES, AND CHALLENGES IN VETERINARY ANALYTICAL METHODS

Variations in metabolism, physiology, and tissue composition difference mean veterinary analytical method validation (AMV) has to be species-specific to facilitate drug absorption, distribution, and residue detection¹⁸. Highly sensitive and specific assays such as LC-MS/MS, capillary electrophoresis, microfluidics, UPLC and high-resolution mass spectrometry show

enhanced sensitivity, specificity, and throughput on various animal matrices. Nevertheless, issues still persist such as absence of a uniformed species specifications, use of different matrices, ethical and logistical limitations, and requirements on resources in order to develop the methods. Addressing these challenges with focused optimization, and strong experimental and technology design, would guarantee reliable, reproducible and regulation-friendly veterinary AMV¹⁹.

3.1 Species-Specific Method Validation

During veterinary analytical method validation, species-specific differences in metabolism and physiology should also be considered as they determine drug absorption, distribution, metabolism and excretion²⁰. Liver enzyme activity, gastrointestinal physiology, and composition of plasma proteins differ greatly among species, causing differences in drug pharmacokinetics as well as in drug detection. Examples include the high contents of plasma protein and complex microbiota in the gut that may affect the binding and bioavailability of drugs thus interfering with residue quantification in ruminants. A comparable issue is that, in aquatic species, lipid amounts in tissues can vary, which can impact extraction and detection thresholds. Hence, the analytical techniques should be optimized on individual species, such as a change in sample preparation, an extraction procedure, and a matrix-specific calibration to make them accurate, precise, and reliable. Failure to respect these species-specific variations may lead to inaccurate data in terms of pharmacokinetics, underrating the quantity of residues or non-compliance regarding the regulations²¹.




Figure 3: In Vitro and In Silico Methods Replacing Animal Tests²²

3.2 Advanced Analytical Techniques

Rapid improvements in analytical technologies have allowed modern veterinary AMV to use high-performance technologies to achieve greater sensitivity, specificity and throughput:

- **LC-MS/MS (Liquid Chromatography-tandem Mass Spectrometry):** The technique scores well in the face of complex matrix such as blood, milk and tissues in terms of residue analysis. It is of high sensitivity so that trace-level compounds could be detected, and of tandem mass spectrometry so that compounds of interest could be better detected than interfering endogenous compounds so it is suited to compliance with maximum residue limits (MRLs)²³.
- **Capillary Electrophoresis (CE) and Microfluidics:** CE can be fast and requires little sample volumes and therefore minimizes reagent costs and analysis time. Microfluidic platforms can be performed in a highly miniaturized and high-throughput format applicable to small laboratory animals or where duplicate samples volume is limited. The two technologies are being used as rapid screening tools, in pharmacokinetics, and to quantify small molecules in veterinary pharmacology.

Other spectroscopic and chromatographic improvements e.g. high-resolution mass spectrometry and ultra- performance liquid chromatography (UPLC) enhance detection levels, reproducibility and method robustness to different animal matrices²⁴.

The recent methods assist in precision medicine practices in veterinary medical care, and they allow precise tracking of drug residues and pharmacology studies with minimal sample volume demand as well as a reduced error rate during the analysis process²⁵.

3.3 Challenges in Veterinary AMV

Although technology has advanced, there are a number of challenges affecting veterinary analytical method validation:

- **No standardized, species-specific guidance:** Most validation frameworks are derived by modification of human or broadly defined veterinary protocols and do not fully cover interspecies variations.
- **Inter-species matrix variability:** The composition of tissues, the amount of proteins and lipids, and other species-specific aspects of the matrix may have significant influence on the extraction efficiency, limits of detection, and even reproducibility of the method, so each species would require more validation steps²⁶.
- **Ethics and feasibility:** Repetitive taking of biological samples on live animals to validate the result is both ethically questionable and a logistical nightmare. Validations may be limited due to availability of limited samples particularly with endangered large laboratory species.
- **Resource-intensive optimization:** There is generally a significant amount of calibration, spiking, and matrix effect testing to be done to develop methods for multiple species, which is time- and cost-consuming to add to laboratory burden.

To tackle such issues, precise experimental design, species-specific optimization, high-level analytical technology, ethical considerations must all be adhered to in ensuring that veterinary AMV delivers results that are reliable, reproducible and regulatory compliant²⁷.

4. EMERGING TRENDS AND INNOVATIONS IN VETERINARY AMV

The field of veterinary analytical method validation (AMV) is currently undergoing a trend of rapid development in relation to technology changes and increasing demands related to accurate, species-specific drug monitoring²⁸. One clear trend has been the incorporation of high-resolution and multidimensional capabilities of the analytical feature platforms, e.g. LC-MS/MS coupled with ion-mobility spectrometry or high-resolution mass spectrometry (HRMS). The approaches allow multiple residues, metabolites, and contaminants to be detectable with higher sensitivity and specificity compared to other methods, which are faster and have better throughput. This is the trend that helps to achieve compliance with regulations and proper monitoring of veterinary drugs in more and more complicated biological matrices.

Table 1: Key Literature on CAR T Cells, Extracellular Vesicles, and Analytical Techniques²⁹

Author(s)	Study	Focus Area	Methodology	Key Finding
Roddie et al. (2019) ³⁰	Manufacturing chimeric antigen receptor T cells: issues and challenges	Production and standardization of CAR T cells	Review and analysis of technical and regulatory challenges in CAR T cell manufacturing	Standardized manufacturing protocols were essential for ensuring safety, reproducibility, and clinical efficacy of CAR T therapies
Rohde et al. (2019) ³¹	Manufacturing and characterization of extracellular vesicles from umbilical cord-derived mesenchymal stromal cells for clinical testing	Standardized production and quality assessment of extracellular vesicles	Experimental study including particle size analysis and protein profiling	Precise characterization techniques were critical for evaluating vesicle functionality and ensuring therapeutic reliability
Schulz et al. (2019) ³²	Advanced MALDI mass spectrometry imaging in pharmaceutical research and drug development	Drug and metabolite distribution mapping in tissues	Literature review of MALDI imaging applications	MALDI imaging enhanced understanding of pharmacokinetics, biodistribution, and contributed to optimizing drug formulations
Schymanski, D et al. (2021) ³³	Analysis of microplastics in drinking water and other clean water samples with micro-Raman and micro-infrared spectroscopy	Detection and quantification of microplastics	Review and guideline development for micro-Raman and micro-infrared spectroscopy	Standardized analytical protocols ensured reliable identification of microplastics and reproducibility across laboratories

Application of microfluidics and chip-on-a-lab technologies is another developing technology. The resulting miniaturized platforms can perform high-throughput analysis with an extremely small sample volume that is of great benefit to studies involving small laboratory animals, or with small amounts of tissue³⁴. Microfluidic devices also save and minimise both the cost and laboratory time of reagent and assures good quality of analytical accuracy. These methods, combined with automated sample preparation systems, can be used to speed veterinary pharmacokinetic and residue studies, providing a means to make decisions quickly within research or a regulatory context.

Veterinary AMV is also undergoing the transformation due to the presence of bioinformatics and chemometrics. High order data processing tools, such as machine learning, and multivariate analysis have been used to better interpret complex data sets produced via chromatography and spectroscopy. Such methods are able to forecast the possibility of matrix impacts, make the optimal method parameters, and increase reproducibility between species and laboratories. Further, bioinformatics assisted validation approaches can enable researchers to simulate pharmacokinetics, predict the variability of intersexual differences, and focus on more rigorous studies, in effect, enhancing the validity and credibility of veterinary drug testing³⁵.

Lastly, environmental conscious and clean methods of analytical chemistry are emerging in veterinary AMV. Methods which reduce solvent use, energy and waste production, including the use of environmentally sound solvents in HPLC or solid-phase microextraction, have become more popular. The innovations conform to the international sustainability policies and at the same time are analytically rigorous. In total, these new trends and innovations show the way towards new, more accurate, efficient, and environmental-friendly search engines which result in veterinary AMV being in the same way of changing trends and the requirements of the new alternations in drug safety, animal welfare, and regulatory positions³⁶.

5. DISCUSSION

The validation of analytical method in veterinary analysis (AMV) is mandatory in the mediation of drug efficacy, safety, and regulatory compliance of animals bearing similarities and differences in several species. Sensitive, precise, and high throughput are advanced methods such as HPLC, LC-MS/MS, microfluidics and bioinformatics, which are used to achieve accurate monitoring of drugs and residues. Although these developments have been made, issues continue to persist: species-specific inconsistencies, ethical implications of sampling, and matrix effects and the lack of commonly accepted guidelines. The future work and studies are suggested then to focus on harmonized regulations, non-invasive or high throughput technologies, machine learning integration, as well as sustainable analytical procedures to increase reliability, efficiency, or environmental compatibility of AMV in veterinary practices³⁷.

5.1 Interpretation and Analysis of Findings

The review points out that veterinary analytical method validation (AMV) is an extremely specific subject area and is influenced due to species-inductions in physiology and metabolism. Recent techniques such as HPLC, UPLC, GC, LC-MS/MS, UV-Vis, and FTIR have high sensitivity, specificity and reproducibility across a wide array of animal matrices allowing the quantification

of drugs, residues, and herbal compounds. There are some main studies of flavonoids-rich herbal extracts in poultry, antibiotics in bovine milk and antiparasitic drugs in aquaculture, which demonstrate the practical efficiency of these approaches and, since such activities are applicable to species and matrices. In addition, high-tech methods like capillary electrophoresis, microfluidics, high-resolution MS and bioinformatics-driven validation methods maximize analytical precision and they are both reduced by size in sample volume and by analysis time to facilitate constructive pharmacokinetic and residue studies.

5.2 Implications and Significance

This data supports the importance of species-specific validation of methods in regard to the safety, efficacy, and regulatory approvals of veterinary drugs. Precise AMV also protects the health of animals, along with prohibiting the build-up of drug residues in animals that we use as food sources and keeps the health of the general population safe by limiting any exposure to any toxic substances. Also, new techniques and trends, e.g. multi-dimensional analytical platforms, microfluidics, chemometrics, and green chemistry methods have recently shown promise of providing an increased throughput, less impact on the environment, and broader reproducibility. These innovations are also friendly to precision veterinary medicine, which enables a more specific treatment towards tailored strategies in dosing and monitoring over different animals, hence, improving the treatment quality and food safety³⁸.

5.3 Identification of Gaps

Despite the developments, there exist a few impediments. Regulatory guidelines lack uniformity and are sorted by species making method transfer and harmonization across laboratories more difficult. The high level of matrix variability, dilemmical issues of the repeated sampling of animals and the costliness of method-development add to the inability of extensive adoption of sound-validation procedures. Moreover, although the newer technologies have potential, they are expensive and complex and need specialized training which act as a limitation in practice especially in settings that have limited resources. The presence of the gaps is evidence that both regulatory and technological interventions must be executed to provide consistent and reliable practices related to AMVs³⁹.

5.4 Future Research Directions

Some future research is in the harmonization of species-specific regulatory frameworks to standardised AMV practice across and between countries. Investigations in non-invasive sampling, miniaturized micro-hydro systems and automated high throughput systems can minimize ethical and practical difficulties. Besides, python machine learning and chemometrics will be used to predict matrix effect and optimize method parameters and inter-laboratory reproducibility to improve analytical precision. Finally, sustainable and environmentally-friendly methodologies in analysis will be a significant aspect of aligning veterinary AMV with the target global environmental objectives whilst at the same time ensuring high standards of quality control. The combined effect of these directions will be the efficacy, the efficiency, and the consistency of veterinary AMV to the changing scientific, regulatory, and ethical demands⁴⁰.

6. CONCLUSION

Veterinary analytical technique confirmation (AMV) is a confined and very expert quality-control constituent in veterinary science, and must be meticulously reliable to confirm drug comfort and proficientness in a wide variety of animal species. Existing techniques such as HPLC, UPLC, GC, LC-MS/MS, UV-Vis, FTIR, among others, offer sensitive specific and reproducible drug residues, and herbal compound analysis, and new technologies including capillary electrophoresis, microfluidics, high-resolution mass-spectrometry, and bioinformatics-based validation protocols offer improved precision, required sample quantity, and faster analysis. Nevertheless, these developments are followed by difficulties in providing species-specific variability, matrix effects, or ethical and logistical restrictions, the lack of harmonized recommendations, and the high costs of the advanced technologies. New emerging trends like multi-dimensional analytical platforms, sustainable chemistry, chemometrics, machine learning and high-throughput systems seem to have solutions to the above challenges and would allow more accurate, efficient and environmentally friendly AMV practices. All these advancements have been able to strengthen the findings on species-specific method of optimization, good experimental design, and innovative practice to protect animal health by ensuring food safety and regulatory compliance-supportive research, and consider possible future research topics to include harmonized and sustainable and technologically enhanced veterinary analytic practices.

REFERENCES

1. Ali, M. M., Hashim, N., Abd Aziz, S., & Lasekan, O. (2020). Principles and recent advances in electronic nose for quality inspection of agricultural and food products. *Trends in Food Science & Technology*, 99, 1-10.
2. Arden, N. S., Fisher, A. C., Tyner, K., Yu, L. X., Lee, S. L., & Kopcha, M. (2021). Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. *International journal of pharmaceutics*, 602, 120554.
3. Balekundri, A., & Mannur, V. (2020). Quality control of the traditional herbs and herbal products: a review. *Future Journal of Pharmaceutical Sciences*, 6(1), 67.
4. Beć, K. B., Grabska, J., & Huck, C. W. (2022). Miniaturized NIR spectroscopy in food analysis and quality control: Promises, challenges, and perspectives. *Foods*, 11(10), 1465.
5. Bitkina, O. V., Kim, H. K., & Park, J. (2020). Usability and user experience of medical devices: An overview of the current state, analysis methodologies, and future challenges. *International Journal of Industrial Ergonomics*, 76, 102932.
6. Broadhurst, D., Goodacre, R., Reinke, S. N., Kuligowski, J., Wilson, I. D., Lewis, M. R., & Dunn, W. B. (2018). Guidelines and considerations for the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic studies. *Metabolomics*, 14(6), 72.
7. Capiiau, S., Veenhof, H., Koster, R. A., Bergqvist, Y., Boettcher, M., Halmingh, O., ... & Alffenaar, J. W. C. (2019). Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring. *Therapeutic drug monitoring*, 41(4), 409-430.

8. Cave, A., Kurz, X., & Arlett, P. (2019). Real-world data for regulatory decision making: challenges and possible solutions for Europe. *Clinical pharmacology and therapeutics*, 106(1), 36.
9. Coppola, L., Cianflone, A., Grimaldi, A. M., Incoronato, M., Bevilacqua, P., Messina, F., ... & Salvatore, M. (2019). Biobanking in health care: evolution and future directions. *Journal of translational medicine*, 17(1), 172.
10. Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., ... & Vicent, M. J. (2022). Current hurdles to the translation of nanomedicines from bench to the clinic. *Drug delivery and translational research*, 12(3), 500-525.
11. Dwyer, J. T., Coates, P. M., & Smith, M. J. (2018). Dietary supplements: regulatory challenges and research resources. *Nutrients*, 10(1), 41.
12. Hussain, C. M., Hussain, C. G., & Keçili, R. (2023). White analytical chemistry approaches for analytical and bioanalytical techniques: Applications and challenges. *TrAC Trends in Analytical Chemistry*, 159, 116905.
13. Jackson, S. A., Schoeni, J. L., Vegge, C., Pane, M., Stahl, B., Bradley, M., ... & Sanders, M. E. (2019). Improving end-user trust in the quality of commercial probiotic products. *Frontiers in microbiology*, 10, 739.
14. Jamróz, W., Szafraniec, J., Kurek, M., & Jachowicz, R. (2018). 3D printing in pharmaceutical and medical applications—recent achievements and challenges. *Pharmaceutical research*, 35(9), 176.
15. Kaza, M., Karaźniewicz-Łada, M., Kosicka, K., Siemiątkowska, A., & Rudzki, P. J. (2019). Bioanalytical method validation: new FDA guidance vs. EMA guideline. Better or worse?. *Journal of pharmaceutical and biomedical analysis*, 165, 381-385.
16. Khan, M. S. A., & Ahmad, I. (2019). Herbal medicine: current trends and future prospects. In *New look to phytomedicine* (pp. 3-13). Academic Press.
17. Kim, H., Lin, Y., & Tseng, T. L. B. (2018). A review on quality control in additive manufacturing. *Rapid Prototyping Journal*, 24(3), 645-669.
18. Kutralam-Muniasamy, G., Shruti, V. C., Pérez-Guevara, F., & Roy, P. D. (2023). Microplastic diagnostics in humans: “The 3Ps” Progress, problems, and prospects. *Science of The Total Environment*, 856, 159164.
19. Lin, A. X., Chan, G., Hu, Y., Ouyang, D., Ung, C. O. L., Shi, L., & Hu, H. (2018). Internationalization of traditional Chinese medicine: current international market, internationalization challenges and prospective suggestions. *Chinese medicine*, 13(1), 9.
20. Manikandan, V. S., Adhikari, B., & Chen, A. (2018). Nanomaterial based electrochemical sensors for the safety and quality control of food and beverages. *Analyst*, 143(19), 4537-4554.
21. Marson, B. M., Concentino, V., Junkert, A. M., Fachi, M. M., Vilhena, R. O., & Pontarolo, R. (2020). Validation of analytical methods in a pharmaceutical quality system: An overview focused on HPLC methods. *Química Nova*, 43, 1190-1203.
22. Mirzaeian, R., Sadoughi, F., Tahmasebian, S., & Mojahedi, M. (2021). The role of herbal medicines in health care quality and the related challenges. *Journal of herbmed pharmacology*, 10(2), 156-165.

23. Mishra, V., Thakur, S., Patil, A., & Shukla, A. (2018). Quality by design (QbD) approaches in current pharmaceutical set-up. *Expert opinion on drug delivery*, 15(8), 737-758.
24. Moosavi, S. M., & Ghassabian, S. (2018). Linearity of Calibration Curves for Analytical Methods: A Review of Criteria for Assessment of Method. *Calibration and validation of analytical methods: a sampling of current approaches*, 109.
25. Mukherjee, P. K. (2019). *Quality control and evaluation of herbal drugs: Evaluating natural products and traditional medicine*. Elsevier.
26. Ohtsu, Y., Tanaka, S., Igarashi, H., Kakehi, M., Mori, T., Nakamura, T., ... & Saito, Y. (2021). Analytical method validation for biomarkers as a drug development tool: points to consider. *Bioanalysis*, 13(18), 1379-1389.
27. Pan, Y., Zhang, H., Chen, Y., Gong, X., Yan, J., & Zhang, H. (2024). Applications of hyperspectral imaging technology combined with machine learning in quality control of traditional Chinese medicine from the perspective of artificial intelligence: a review. *Critical Reviews in Analytical Chemistry*, 54(8), 2850-2864.
28. Raclariu, A. C., Heinrich, M., Ichim, M. C., & de Boer, H. (2018). Benefits and limitations of DNA barcoding and metabarcoding in herbal product authentication. *Phytochemical Analysis*, 29(2), 123-128.
29. Richardson, S. D., & Ternes, T. A. (2018). Water analysis: emerging contaminants and current issues. *Anal. Chem*, 90(1), 398-428.
30. Roddie, C., O'Reilly, M., Pinto, J. D. A., Vispute, K., & Lowdell, M. (2019). Manufacturing chimeric antigen receptor T cells: issues and challenges. *Cytotherapy*, 21(3), 327-340.
31. Rohde, E. V. A., Pachler, K., & Gimona, M. (2019). Manufacturing and characterization of extracellular vesicles from umbilical cord-derived mesenchymal stromal cells for clinical testing. *Cytotherapy*, 21(6), 581-592.
32. Schulz, S., Becker, M., Groseclose, M. R., Schadt, S., & Hopf, C. (2019). Advanced MALDI mass spectrometry imaging in pharmaceutical research and drug development. *Current opinion in biotechnology*, 55, 51-59.
33. Schymanski, D., Oßmann, B. E., Benismail, N., Boukerma, K., Dallmann, G., Von der Esch, E., ... & Ivleva, N. P. (2021). Analysis of microplastics in drinking water and other clean water samples with micro-Raman and micro-infrared spectroscopy: minimum requirements and best practice guidelines. *Analytical and bioanalytical chemistry*, 413(24), 5969-5994.
34. Segers, K., Declerck, S., Mangelings, D., Heyden, Y. V., & Eeckhaut, A. V. (2019). Analytical techniques for metabolomic studies: A review. *Bioanalysis*, 11(24), 2297-2318.
35. Sharma, S., Goyal, S., & Chauhan, K. (2018). A review on analytical method development and validation. *International Journal of Applied Pharmaceutics*, 10(6), 8-15.
36. Su, Q., Ganesh, S., Moreno, M., Bommireddy, Y., Gonzalez, M., Reklaitis, G. V., & Nagy, Z. K. (2019). A perspective on Quality-by-Control (QbC) in pharmaceutical continuous manufacturing. *Computers & Chemical Engineering*, 125, 216-231.
37. Sullivan, S., Stacey, G. N., Akazawa, C., Aoyama, N., Baptista, R., Bedford, P., ... & Song, J. (2018). Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. *Regenerative medicine*, 13(7), 859-866.
38. Sulyok, M., Stadler, D., Steiner, D., & Krska, R. (2020). Validation of an LC-MS/MS-based dilute-and-shoot approach for the quantification of > 500 mycotoxins and other secondary

metabolites in food crops: Challenges and solutions. Analytical and bioanalytical chemistry, 412(11), 2607-2620.

39. Vaou, N., Stavropoulou, E., Voidarou, C., Tsigalou, C., & Bezirtzoglou, E. (2021). Towards advances in medicinal plant antimicrobial activity: A review study on challenges and future perspectives. *Microorganisms*, 9(10), 2041.
40. Wang, H., Chen, Y., Wang, L., Liu, Q., Yang, S., & Wang, C. (2023). Advancing herbal medicine: enhancing product quality and safety through robust quality control practices. *Frontiers in pharmacology*, 14, 1265178.